India Groups Unite To Challenge Herceptin Breast Cancer Patent (India)
This article was originally published in PharmAsia News
Executive Summary
Groups in India are organizing to challenge the patent granted F. Hoffman-LaRoche for its Herceptin (trastuzumb) for fighting breast cancer. The challengers have formed the Lawyers Collective to fight for women's issues, arguing in this case that giving the drug patent protection denies millions of women with the cancer from having access to cheap versions. The same group challenged a Novartis application for a patent on its Gleevec (imatinib mesylate) in 2005, and litigation continues. (Click here for more
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.